MiR-382 inhibits osteosarcoma metastasis and relapse by targeting y box-binding protein 1

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 89-98

  Xu, Meng ^a   Jin, Hua ^b   Xu, Cheng Xiong ^c   Sun, Bo ^d   Song, Zhi Gang ^a   Bi, Wen Zhi ^a   Wang, Yan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MICRORNA 382; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1; ANTINEOPLASTIC ANTIBIOTIC; MICRORNA; MIRN382 MICRORNA, HUMAN; YBX1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RECURRENCE; CANCER STEM CELL; CHILD; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; METASTASIS INHIBITION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOSARCOMA; PROTEIN TARGETING; REGULATORY MECHANISM; ANIMAL; BONE NEOPLASMS; CELL MOTION; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PLASMID; PRESCHOOL CHILD; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADOLESCENT; ADULT; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OSTEOSARCOMA; PLASMIDS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; Y-BOX-BINDING PROTEIN 1;

EID: 84920701509     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.197     Document Type: Article

References (49)

1. Messerschmitt, PJ, Garcia, RM, Abdul-Karim, FW, Greenfeld, EM and Getty, PJ (2009). Osteosarcoma. J Am Acad Orthop Surg 17: 515-527.
2. Thayanithy, V, Sarver, AL, Kartha, RV, Li, L, Angstadt, AY, Breen, M et al. (2012). Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone 50: 171-181.
3. Broadhead, ML, Clark, JC, Myers, DE, Dass, CR and Choong, PF (2011). The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011: 959248.
4. Marulanda, GA, Henderson, ER, Johnson, DA, Letson, GD and Cheong, D (2008). Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control 15: 13-20.
5. Huang, J, Ni, J, Liu, K, Yu, Y, Xie, M, Kang, R et al. (2012). HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 72: 230-238.
6. PosthumaDeBoer, J, Witlox, MA, Kaspers, GJ and van Royen, BJ (2011). Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 28: 493-503.
7. Bielack, SS, Kempf-Bielack, B, Branscheid, D, Carrle, D, Friedel, G, Helmke, K et al. (2009). Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27: 557-565.
8. Marina, N, Gebhardt, M, Teot, L and Gorlick, R (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441.
9. Liu, C and Tang, DG (2011). MicroRNA regulation of cancer stem cells. Cancer Res 71: 5950-5954.
10. Yu, Y, Ramena, G and Elble, RC (2012). The role of cancer stem cells in relapse of solid tumors. Front Biosci (Elite Ed) 4: 1528-1541.
11. Gibbs, CP, Kukekov, VG, Reith, JD, Tchigrinova, O, Suslov, ON, Scott, EW et al. (2005). Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976.
12. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identifcation of human brain tumour initiating cells. Nature 432: 396-401.
13. Du, L, Rao, G, Wang, H, Li, B, Tian, W, Cui, J et al. (2013). CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res 73: 2682-2694.
14. Pardal, R, Clarke, MF and Morrison, SJ (2003). Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
15. Iliopoulos, D, Lindahl-Allen, M, Polytarchou, C, Hirsch, HA, Tsichlis, PN and Struhl, K (2010). Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39: 761-772.
16. Xu, Y, Wang, J, Li, X, Liu, Y, Dai, L, Wu, X et al. (2014). Selective inhibition of breast cancer stem cells by gold nanorods mediated plasmonic hyperthermia. Biomaterials. 35: 4667-4677.
17. Ceppi, P and Peter, ME (2014). MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene 33: 269-278.
18. Magee, JA, Piskounova, E and Morrison, SJ (2012). Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-296.
19. Song, SJ, Poliseno, L, Song, MS, Ala, U, Webster, K, Ng, C et al. (2013). MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154: 311-324.
20. Miranda, KC, Huynh, T, Tay, Y, Ang, YS, Tam, WL, Thomson, AM et al. (2006). A pattern-based method for the identifcation of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203-1217.
21. Bhattacharya, A, Ziebarth, JD and Cui, Y (2013). SomamiR: a database for somatic mutations impacting microRNA function in cancer. Nucleic Acids Res 41(Database issue): D977-D982.
22. Gregory, PA, Bert, AG, Paterson, EL, Barry, SC, Tsykin, A, Farshid, G et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
23. Gregory, PA, Bracken, CP, Smith, E, Bert, AG, Wright, JA, Roslan, S et al. (2011). An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 22: 1686-1698.
24. Mateescu, B, Batista, L, Cardon, M, Gruosso, T, de Feraudy, Y, Mariani, O et al. (2011). miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 17: 1627-1635.
25. Li, Z, Lu, J, Sun, M, Mi, S, Zhang, H, Luo, RT et al. (2008). Distinct microRNA expression profles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 105: 15535-15540.
26. Sarver, AL, Thayanithy, V, Scott, MC, Cleton-Jansen, AM, Hogendoorn, PC, Modiano, JF et al. (2013). MicroRNAs at the human 14q32 locus have prognostic signifcance in osteosarcoma. Orphanet J Rare Dis 8: 7.
27. Gupta, GP and Massagué, J (2006). Cancer metastasis: building a framework. Cell 127: 679-695.
28. Pelicci, PG, Dalton, P and Orecchia, R (2011). Heating cancer stem cells to reduce tumor relapse. Breast Cancer Res 13: 305.
29. Mouneimne, G and Brugge, JS (2009). YB-1 translational control of epithelial-mesenchyme transition. Cancer Cell 15: 357-359.
30. Zhang, H, Cheng, S, Zhang, M, Ma, X, Zhang, L, Wang, Y et al. (2014). Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression. Int J Oncol 44: 769-780.
31. Stratford, AL, Reipas, K, Hu, K, Fotovati, A, Brough, R, Frankum, J et al. (2012). Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells 30: 1338-1348.
32. Fotovati, A, Abu-Ali, S, Wang, PS, Deleyrolle, L P, Lee, C, Triscott, J et al. (2011). YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res 71: 5569-5578.
33. Fujiwara-Okada, Y, Matsumoto, Y, Fukushi, J, Setsu, N, Matsuura, S, Kamura, S et al. (2013). Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer 108: 836-847.
34. Oda, Y, Ohishi, Y, Saito, T, Hinoshita, E, Uchiumi, T, Kinukawa, N et al. (2003). Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 199: 251-258.
35. Yang, G, Yuan, J and Li, K (2013). EMT transcription factors: implication in osteosarcoma. Med Oncol 30: 697.
36. Siclari, VA and Qin, L (2010). Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 5: 78.
37. Evdokimova, V, Tognon, C, Ng, T, Ruzanov, P, Melnyk, N, Fink, D et al. (2009). Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15: 402-415.
38. Evdokimova, V, Tognon, C, Ng, T and Sorensen, PH (2009). Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 8: 2901-2906.
39. Dhillon, J, Astanehe, A, Lee, C, Fotovati, A, Hu, K and Dunn, SE (2010). The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene 29: 6294-6300.
40. To, K, Fotovati, A, Reipas, KM, Law, JH, Hu, K, Wang, J et al. (2010). Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 70: 2840-2851.
41. Civenni, G, Malek, A, Albino, D, Garcia-Escudero, R, Napoli, S, Di Marco, S et al. (2013). RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res 73: 6816-6827.
42. Amatangelo, MD, Goodyear, S, Varma, D and Stearns, ME (2012). c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer. Carcinogenesis 33: 1965-1975.
43. Kriegel, AJ, Fang, Y, Liu, Y, Tian, Z, Mladinov, D, Matus, IR et al. (2010). MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: a novel role of miR-382. Nucleic Acids Res 38: 8338-8347.
44. Korpal, M, Ell, BJ, Buffa, FM, Ibrahim, T, Blanco, MA, Celià-Terrassa, T et al. (2011). Direct targeting of Sec23a by miR-200s infuences cancer cell secretome and promotes metastatic colonization. Nat Med 17: 1101-1108.
45. Li, J, Huang, H, Sun, L, Yang, M, Pan, C, Chen, W et al. (2009). MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15: 3998-4008.
46. Xu, CX, Jere, D, Jin, H, Chang, SH, Chung, YS, Shin, JY et al. (2008). Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med 178: 60-73.
47. Graat, HC, Witlox, MA, Schagen, FH, Kaspers, GJ, Helder, MN, Bras, J et al. (2006). Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J Cancer 94: 1837-1844.
48. Tirino, V, Desiderio, V, Paino, F, De Rosa, A, Papaccio, F, Fazioli, F et al. (2011). Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 25: 2022-2030.
49. Basu-Roy, U, Seo, E, Ramanathapuram, L, Rapp, TB, Perry, JA, Orkin, SH et al. (2012). Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 31: 2270-2282.